Vivesto AB (VIVE.ST)
SEK 0.27
(-1.45%)
SEK 0.27
(-1.45%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 8.16 Million SEK | -21.67% |
| 2021 | 10.42 Million SEK | 0.0% |
| 2020 | - SEK | -100.0% |
| 2019 | 94.16 Million SEK | -32.53% |
| 2018 | 139.56 Million SEK | -25.47% |
| 2017 | 187.26 Million SEK | 10.98% |
| 2016 | 168.72 Million SEK | 20.57% |
| 2015 | 139.94 Million SEK | 30.79% |
| 2014 | 107 Million SEK | -26.21% |
| 2013 | 145 Million SEK | 38.1% |
| 2012 | 105 Million SEK | 220.15% |
| 2011 | 32.79 Million SEK | 0.0% |
| 2010 | - SEK | -100.0% |
| 2009 | 14.83 Million SEK | -44.7% |
| 2008 | 26.83 Million SEK | 85.2% |
| 2007 | 14.48 Million SEK | 488.7% |
| 2006 | 2.46 Million SEK | -16.23% |
| 2005 | 2.93 Million SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 6.97 Million SEK | -11.59% |
| 2023 Q1 | 7.89 Million SEK | -3.37% |
| 2022 Q2 | 6.81 Million SEK | -11.93% |
| 2022 Q4 | 8.16 Million SEK | 30.81% |
| 2022 FY | 8.16 Million SEK | -21.67% |
| 2022 Q3 | 6.24 Million SEK | -8.39% |
| 2022 Q1 | 7.73 Million SEK | -25.79% |
| 2021 Q3 | 92.11 Million SEK | 1.7% |
| 2021 Q2 | 90.57 Million SEK | 5.11% |
| 2021 FY | 10.42 Million SEK | 0.0% |
| 2021 Q1 | 86.17 Million SEK | 0.0% |
| 2021 Q4 | 10.42 Million SEK | -88.68% |
| 2020 Q2 | 92.84 Million SEK | -1.41% |
| 2020 Q4 | - SEK | -100.0% |
| 2020 FY | - SEK | -100.0% |
| 2020 Q3 | 92.09 Million SEK | -0.81% |
| 2020 Q1 | 94.16 Million SEK | 4.43% |
| 2019 Q4 | 90.17 Million SEK | -1.2% |
| 2019 Q1 | 139.56 Million SEK | 62.69% |
| 2019 FY | 94.16 Million SEK | -32.53% |
| 2019 Q2 | 153.38 Million SEK | 9.9% |
| 2019 Q3 | 91.26 Million SEK | -40.5% |
| 2018 Q3 | 123.38 Million SEK | -26.75% |
| 2018 Q4 | 85.78 Million SEK | -30.47% |
| 2018 Q2 | 168.44 Million SEK | -10.05% |
| 2018 FY | 139.56 Million SEK | -25.47% |
| 2018 Q1 | 187.26 Million SEK | 16.11% |
| 2017 FY | 187.26 Million SEK | 10.98% |
| 2017 Q4 | 161.27 Million SEK | 16.7% |
| 2017 Q3 | 138.19 Million SEK | -14.06% |
| 2017 Q2 | 160.8 Million SEK | -4.69% |
| 2017 Q1 | 168.72 Million SEK | 2.35% |
| 2016 Q1 | 139.94 Million SEK | 22.3% |
| 2016 FY | 168.72 Million SEK | 20.57% |
| 2016 Q4 | 164.85 Million SEK | 0.82% |
| 2016 Q3 | 163.51 Million SEK | -7.53% |
| 2016 Q2 | 176.82 Million SEK | 26.36% |
| 2015 Q2 | - SEK | -100.0% |
| 2015 Q4 | 114.43 Million SEK | 1.09% |
| 2015 Q1 | 107 Million SEK | 0.0% |
| 2015 FY | 139.94 Million SEK | 30.79% |
| 2015 Q3 | 113.19 Million SEK | 0.0% |
| 2014 Q1 | 145 Million SEK | 784.63% |
| 2014 Q4 | 107 Million SEK | -26.21% |
| 2014 Q3 | 145 Million SEK | 0.0% |
| 2014 Q2 | 145 Million SEK | 0.0% |
| 2014 FY | 107 Million SEK | -26.21% |
| 2013 Q1 | 105 Million SEK | 762.21% |
| 2013 FY | 145 Million SEK | 38.1% |
| 2013 Q3 | 105 Million SEK | 0.0% |
| 2013 Q4 | 16.39 Million SEK | -84.39% |
| 2013 Q2 | 105 Million SEK | 0.0% |
| 2012 Q1 | 32.79 Million SEK | 0.0% |
| 2012 Q4 | 12.17 Million SEK | -88.89% |
| 2012 FY | 105 Million SEK | 220.15% |
| 2012 Q2 | 90 Million SEK | 174.42% |
| 2012 Q3 | 109.65 Million SEK | 21.83% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | 32.79 Million SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q4 | - SEK | -100.0% |
| 2010 FY | - SEK | -100.0% |
| 2010 Q3 | 74.25 Million SEK | 78.77% |
| 2010 Q2 | 41.53 Million SEK | 179.9% |
| 2010 Q1 | 14.83 Million SEK | 0.0% |
| 2009 FY | 14.83 Million SEK | -44.7% |
| 2008 FY | 26.83 Million SEK | 85.2% |
| 2007 FY | 14.48 Million SEK | 488.7% |
| 2006 FY | 2.46 Million SEK | -16.23% |
| 2005 FY | 2.93 Million SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | 7.182% |
| Enzymatica AB (publ) | 26.1 Million SEK | 68.709% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -1773.394% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | 56.856% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | -72.43% |
| Nanexa AB (publ) | 4.03 Million SEK | -102.579% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | 98.276% |
| Probi AB (publ) | 53.79 Million SEK | 84.817% |
| Swedencare AB (publ) | 1.65 Billion SEK | 99.508% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 99.96% |
| Toleranzia AB | 850 Thousand SEK | -860.941% |